Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III first-line capivasertib plus paclitaxel versus placebo plus paclitaxel in advanced or metastatic triple-negative breast cancer
CTR20192096Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of capivasertib in triple-negative breast cancer (TNBC), sponsored by AstraZeneca. Started Aug 2021; status: active.
02
Drugs
capivasertib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on CTR20192096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192096.